クイック注文

Interferon beta/IFN-beta/IFNB1  Protein, Antibody, ELISA Kit, cDNA Clone

発現宿主: CHO Stable Cells  
10704-HNAS-500
10704-HNAS-5
10704-HNAS-20
10704-HNAS-100
10704-HNAS-1
500 µg 
5 µg 
20 µg 
100 µg 
1 mg 
Add to Cart
  • Slide 1
製品の説明: Active  
発現宿主: Human Cells  
10704-H02H-5
10704-H02H-20
10704-H02H-100
5 µg 
20 µg 
100 µg 
Add to Cart
  • Slide 1
製品の説明: Active  
発現宿主: Human Cells  
50708-MCCH-5
50708-MCCH-20
50708-MCCH-100
5 µg 
20 µg 
100 µg 
Add to Cart
  • Slide 1
製品の説明: Active  
発現宿主: Human Cells  
50708-M02H-5
50708-M02H-20
50708-M02H-100
5 µg 
20 µg 
100 µg 
Add to Cart
  • Slide 1
発現宿主: Human Cells  
90104-C05H-5
90104-C05H-20
90104-C05H-100
5 µg 
20 µg 
100 µg 
Add to Cart
  • Slide 1

Interferon beta/IFN-beta/IFNB1 Related Area

Interferon beta/IFN-beta/IFNB1 関連経路

    Interferon beta/IFN-beta/IFNB1 関連製品

    Interferon beta/IFN-beta/IFNB1 サマリー & タンパク質情報

    Interferon beta/IFN-beta/IFNB1 背景

    サブユニット構造: Monomer. Signals mostly via binding to a IFNAR1-IFNAR2 heterodimeric receptor, but can also function with IFNAR1 alone and independently of Jak-STAT pathways.
    細胞内位置: Secreted.
    シーケンスの類似性: Belongs to the alpha/beta interferon family. {ECO:0000305}.
    General information above from UniProt

    Interferons (IFNs) are natural glycoproteins belonging to the cytokine superfamily, and are produced by the cells of the immune system of most vertebrates in response to challenges by foreign agents such as viruses, parasites and tumor cells. Interferon-beta (IFN beta) is an extra-cellular protein mediator of host defense and homeostasis. IFN beta has well-established direct antiviral, antiproliferative and immunomodulatory properties. Recombinant IFN beta is approved for the treatment of relapsing-remitting multiple sclerosis. The recombinant IFN beta protein has the theoretical potential to either treat or cause autoimmune neuromuscular disorders by altering the complicated and delicate balances within the immune system networks. It is the most widely prescribed disease-modifying therapy for multiple sclerosis (MS). Large-scale clinical trials have established the clinical efficacy of IFN beta in reducing relapses and slowing disease progression in relapsing-remitting MS. IFN beta therapy was shown to be comparably beneficial for opticospinal MS (OSMS) and conventional MS in Japanese. IFN beta is effective in reducing relapses in secondary progressive MS and may have a modest effect in slowing disability progression. In addition to the common antiviral activity, IFN beta also induces increased production of the p53 gene product which promotes apoptosis, and thus has therapeutic effect against certain cancers. The role of IFN-beta in bone metabolism could warrant its systematic evaluation as a potential adjunct to therapeutic regimens of osteolytic diseases. Furthermore, IFN beta might play a beneficial role in the development of a chronic progressive CNS inflammation.

    Immune Checkpoint   Immunotherapy   Cancer Immunotherapy   Targeted Therapy

    Interferon beta/IFN-beta/IFNB1 代替名

    Interferon beta,IFB,IFF, []
    IFB,IFF,IFNB, [homo-sapiens]
    IFN beta,IFNB, [human]
    Ifb,IFN beta,IFNB,Ifnb1,RP23-19G2.2, [mouse]
    Ifb,IFNB,IFN-beta, [mus-musculus]

    Interferon beta/IFN-beta/IFNB1 関連研究

  • Kohriyama T, et al. (2008) Interferon-beta treatment for multiple sclerosis and predictors of response. Nippon Rinsho. 66(6): 1119-26.
  • Stbgen JP. (2009) Recombinant interferon-beta therapy and neuromuscular disorders. J Neuroimmunol. 212(1-2): 132-41.
  • Abraham AK, et al. (2009) Mechanisms of interferon-beta effects on bone homeostasis. Biochem Pharmacol. 77(12): 1757-62.
  • 注意:すべての製品は、"研究目的のみに使用するものであり、診断または治療目的に使用するものではありません"